| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $5,157,754 | 4 | 33 |
Sells | $37,794 | 8 | 67 |
| GOODMAN COREY S | 1 | $5M | 0 | $0 | $5M | |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2 | $99,352 | 2 | $28,240 | $71,112 |
| Shantharam Harish | Chief Financial Officer | 1 | $58,403 | 0 | $0 | $58,403 |
| Pinto Shelly | SVP, FINANCE AND CAO | 0 | $0 | 6 | $9,554 | $-9,554 |
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology firm focused on developing innovative therapies for cancer patients. At the forefront of its pipeline is ALX148, a CD47 blocking therapeutic, which is progressing through Phase 1b/2 clinical trials. This candidate is being evaluated for a variety of hematologic malignancies, including myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma. Additionally, it targets a range of solid tumors, such as head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumor indications. Beyond its lead candidate, ALX Oncology's pre-clinical portfolio includes ALTA-002, a SIRPa TRAAC designed to engage both the innate and adaptive immune systems in the fight against cancer. The company maintains a robust network of strategic collaborations, including a Phase 2 trial with Merck evaluating ALX148 in combination with pembrolizumab (with or without chemotherapy) for head and neck cancer. Another partnership involves Zymeworks for a Phase 1 trial assessing ALX148 alongside the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors. Furthermore, ALX Oncology collaborates with Tallac Therapeutics for the development, manufacturing, and commercialization of a novel class of cancer immunotherapeutics. Further bolstering its capabilities are licensing agreements with Selexis SA and Crystal Bioscience, Inc. Founded in 2015, the company operates from its headquarters in South San Francisco, California.
Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $5.16M and sold $37,794 worth of ALX Oncology Holdings Inc. stock.
On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $1.79M and sold $7.38M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GOODMAN COREY S () — $5M. Lettmann Jason (CHIEF EXECUTIVE OFFICER) — $99,352. Shantharam Harish (Chief Financial Officer) — $58,403.
The last purchase of 3,184,713 shares for transaction amount of $5M was made by GOODMAN COREY S () on 2026‑02‑02.
| 2026-03-19 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 12,311 0.0225% | $2.17 | $26,715 | -14.36% | |
| 2026-03-19 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 903 0.0017% | $2.17 | $1,960 | -14.36% | |
| 2026-02-18 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 565 0.001% | $2.27 | $1,283 | -15.52% | |
| 2026-02-02 | GOODMAN COREY S | 3.18M 5.4893% | $1.57 | $5M | +17.86% | |||
| 2026-01-06 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 3,925 0.0072% | $1.11 | $4,357 | +81.02% | |
| 2025-09-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 71,163 0.1367% | $1.08 | $76,892 | +61.43% | ||
| 2025-09-16 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 21,070 0.0388% | $1.07 | $22,461 | +56.48% | ||
| 2025-08-18 | Shantharam Harish | Chief Financial Officer | 75,000 0.1123% | $0.78 | $58,403 | +68.92% | ||
| 2025-08-15 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,382 0.0044% | $0.64 | $1,525 | +154.54% | |
| 2025-08-15 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 611 0.0011% | $0.64 | $391 | +154.54% | |
| 2025-07-07 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 2,011 0.0038% | $0.45 | $905 | +250.23% | |
| 2025-06-30 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 1,532 0.003% | $0.43 | $659 | +273.40% | |
| 2025-02-19 | Sale | Pons Jaume | PRESIDENT & CSO | 1,326 0.0025% | $1.15 | $1,525 | -10.92% | |
| 2025-02-19 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,159 0.004% | $1.15 | $2,483 | -10.92% | |
| 2025-02-19 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 550 0.001% | $1.15 | $633 | -10.92% | |
| 2025-01-06 | Sale | Pinto Shelly | Interim CFO | 2,221 0.0043% | $1.80 | $3,998 | -41.06% | |
| 2024-12-30 | Sale | Pons Jaume | PRESIDENT & CSO | 10,796 0.02% | $1.58 | $17,060 | -36.45% | |
| 2024-12-30 | Sale | Pinto Shelly | Interim CFO | 1,426 0.0026% | $1.58 | $2,253 | -36.45% | |
| 2024-12-02 | Hemrajani Rekha | director | 30,000 0.0532% | $1.55 | $46,404 | -36.45% | ||
| 2024-08-14 | Sale | Pons Jaume | PRESIDENT & CSO | 1,937 0.0038% | $2.58 | $4,997 | -56.98% |
| GOODMAN COREY S | 8453038 6.2818% | $12.85M | 2 | 0 | +90.48% | |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 293609 0.2182% | $446,285.68 | 4 | 7 | +4.84% |
| Pinto Shelly | SVP, FINANCE AND CAO | 86805 0.0645% | $131,943.60 | 0 | 17 | |
| Shantharam Harish | Chief Financial Officer | 75000 0.0557% | $114,000.00 | 1 | 0 | |
| Adelman Robert J | 5268325 3.9151% | $8.01M | 1 | 0 | +90.48% | |
| Graham G. Walmsley | director | 995000 0.7394% | $1.51M | 2 | 0 | +34.88% |
| Vivo Capital IX, LLC | 10 percent owner | 789474 0.5867% | $1.2M | 1 | 0 | +90.48% |
| Pons Jaume | PRESIDENT & CSO | 579388 0.4306% | $880,669.76 | 0 | 20 | |
| Randolph Sophia | CHIEF MEDICAL OFFICER | 325711 0.2421% | $495,080.72 | 0 | 15 | |
| LSV Associates, LLC | 10 percent owner | 285956 0.2125% | $434,653.12 | 1 | 4 | +90.48% |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 122348 0.0909% | $185,968.96 | 2 | 8 | +4.18% |
| Hemrajani Rekha | director | 33000 0.0245% | $50,160.00 | 2 | 0 | +27.02% |
| Pietzke Steffen | VP Fin & Chief Acct Officer | 3000 0.0022% | $4,560.00 | 1 | 0 | +90.48% |
$9,456,760 | 65 | 2.69% | $219.06M | |
$24,442,471 | 44 | -29.96% | $228.59M | |
$130,095 | 43 | 45.19% | $231.68M | |
$295,092,700 | 21 | -0.27% | $229.62M | |
$20,234,041 | 17 | 2.09% | $203.97M | |
$448,999,793 | 15 | -19.99% | $197.47M | |
$1,037,470 | 13 | 78.00% | $198.11M | |
ALX Oncology Holdings Inc. (ALXO) | $156,530,514 | 13 | 45.71% | $204.54M |
$15,799,576 | 12 | -39.52% | $214.02M | |
$19,167,169 | 10 | 28.48% | $192.1M | |
$2,762,881 | 8 | -10.76% | $220.49M | |
$145,296,407 | 8 | -0.98% | $209.06M | |
$119,804,612 | 8 | -17.22% | $200.24M | |
$164,999,952 | 5 | -44.44% | $197.73M | |
$4,745,999 | 5 | -4.91% | $232.78M | |
$32,007,657 | 4 | -45.65% | $193.92M | |
$193,101 | 3 | -25.20% | $192.48M | |
$15,551,156 | 3 | 98.82% | $203.8M | |
$63,731 | 1 | -19.50% | $209.5M |
| Increased Positions | 27 | +39.71% | 3M | +10.28% |
| Decreased Positions | 26 | -38.24% | 1M | -5.11% |
| New Positions | 9 | New | 237,671 | New |
| Sold Out Positions | 10 | Sold Out | 1M | Sold Out |
| Total Postitions | 69 | +1.47% | 29M | +5.17% |
| Venbio Partners Llc | $11,155.00 | 17.96% | 9.7M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $3,833.00 | 6.17% | 3.33M | -58,472 | -1.72% | 2025-09-30 |
| Millennium Management Llc | $3,016.00 | 4.86% | 2.62M | +2M | +432.44% | 2025-09-30 |
| Almitas Capital Llc | $2,917.00 | 4.7% | 2.54M | -1,464 | -0.06% | 2025-09-30 |
| Vanguard Group Inc | $1,758.00 | 2.83% | 1.53M | -72,189 | -4.51% | 2025-09-30 |
| Acadian Asset Management Llc | $1,404.00 | 2.26% | 1.22M | -47,174 | -3.72% | 2025-09-30 |
| Driehaus Capital Management Llc | $915.00 | 1.47% | 795,777 | +795,777 | New | 2025-09-30 |
| Two Sigma Advisers, Lp | $828.00 | 1.33% | 719,800 | +16,500 | +2.35% | 2025-09-30 |
| Ameriprise Financial Inc | $751.00 | 1.21% | 652,897 | +652,897 | New | 2025-09-30 |
| Two Sigma Investments, Lp | $698.00 | 1.12% | 606,671 | +128,737 | +26.94% | 2025-09-30 |